Official Signing Ceremony for WIBP Strategic Alliance

MONTREAL, June 5 /PRNewswire-FirstCall/ -- ProMetic Life Sciences Inc.
(TSX: PLI) ("ProMetic") announced today that the official signing ceremony
for the strategic alliance concluded earlier this year with the Wuhan
Institute of Biological Products ("WIBP") a subsidiary of China National
Biotec Group ("CNBG") was held on Wednesday, June 4, 2008 at CNBG's Beijing
location.

Present at the signing were CNBG's President and Chief Executive
Officer Ms. Lifeng Wang, WIBP's Director Dr. Xiaoming Yang, ProMetic's
President and Chief Executive Officer Mr. Pierre Laurin as well as several
officials from the CNBG and WIBP organizations. Additional information is
available on CNBG's web site at http://www.cnbgint.com and on WIBP's web site at
http://www.wibp.com.cn/en.

More about Wuhan Institute of Biological Products

WIBP (http://www.wibp.com.cn or http://www.wibp.com.cn/en), located in Wuhan, China.
is one of the subsidiaries of CNBG, has over 50 years experience in the
fields of biomedical research and product development; historically strong
in R&D, WIBP is the only institute certified by state to offer doctoral
program among six Institute of Biological Products in CNBG. Today, WIBP has
more than 1,000 employees, and major products include two dozen vaccines
and plasma derivatives currently marketed throughout the China.

More about China National Biotec Group

CNBG (http://www.cnbgint.com or http://www.cnbg.com.cn), headquartered in Beijing,
China, is a state-owned enterprise and the largest biotech company in China
dedicated to discover, develop, manufacture and market a broad range of
human health products, including vaccines, blood derivatives,
biopharmaceuticals, diagnostic reagents and others. With more than 9,000
employees and revenues of 421 million USD in 2006, CNBG is the largest
producer of vaccines and blood derivatives in China, enjoying more than 80%
and 30% market share respectively. The company consists of 6 Institute of
Biological Products and an international trading company.

About ProMetic Life Sciences Inc.

ProMetic (http://www.prometic.com) is a biopharmaceutical company specialized
in the research, development, manufacture and marketing of a variety of
commercial applications derived from its proprietary Mimetic Ligand(TM)
technology. This technology is used in large-scale purification of
biologics and the elimination of pathogens. ProMetic is also active in
therapeutic drug development with the mission to bring to market effective,
innovative, lower cost, less toxic products for the treatment of hematology
and cancer. Its drug discovery platform is focused on replacing complex,
expensive proteins with synthetic "drug-like" protein mimetics.
Headquartered in Montreal (Canada), ProMetic has R&D facilities in the
U.K., the U.S. and Canada, manufacturing facilities in the U.K. and
business development activities in the U.S., Europe, Asia and in the
Middle-East.

See Also:

• Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma



• Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.



• Interface Biologics Inc. achieves reductions in platelet adhesion similar to heparin coated devices with use of non drug surface additive



• New Book Presents Simple Scientific Approach for Better Sleep and Reduced Cancer Risk



• San Diego Dentist Dr. Ernest Wong Now Offers One-Appointment CEREC Porcelain Crowns

[Via Healthcare]